Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;26(11):1464-1466.
doi: 10.18553/jmcp.2020.26.11.1464.

ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine

Meg Franklin  1 , Eric Druyts  2
Affiliations

ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine

Meg Franklin et al. J Manag Care Spec Pharm. 2020 Nov.

Abstract

DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.

PubMed Disclaimer

Conflict of interest statement

No funding supported the writing of this commentary. The authors have nothing to disclose.

References

    1. Agosti R. Migraine burden of disease: from the patient’s experience to a socioeconomic view. Headache. 2018;58 (Suppl 1):17-32. - PubMed
    1. Nicolas S, Nicolas D.. Triptans. In: StatPearls. Updated May 26, 2020. StatPearls Publishing. Accessed October 1, 2020. https://www.ncbi.nlm.nih.gov/books/NBK554507/
    1. Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17(1):107. - PMC - PubMed
    1. Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304-12. - PMC - PubMed
    1. Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8(1):46-54. - PMC - PubMed